Drug intelligence / Profile preview

ES-2301

Development stage: Unknown
Lead developer: Eusol Biotech
Modality: Recombinant Proteins and Enzymes
Administration: Intralesional

Overview

ES-2301 is a recombinant human acidic fibroblast growth factor (rhFGF1) biologic developed by Eusol Biotech. It is designed to promote nerve regeneration and tissue repair by acting as an agonist for fibroblast growth factor receptors (FGFR). The drug is primarily being investigated for the treatment of carpal tunnel syndrome (CTS), where it is administered via local injection to the affected area. ES-2301 has completed Phase 2 clinical evaluation for this indication and is closely related to the compound ES135, which has been studied for spinal cord injury.

Other names: rhFGF1rhFGF-1rhFGF 1recombinant human acidic fibroblast growth factorFGF1FGF-1FGF 1

Targets

FGFR3 (Fibroblast growth factor receptor 3)

Beyond the preview

Go deeper on ES-2301.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ES-2301.

Explore the full profile